Viagra has finally been knocked off its No.1 position in the global market for erectile dysfunction medication by Cialis. In March Viagra claimed about 39% of the market whilst Cialis captured 41% according to IMS Health data. This is a historical “first” and a remarkable milestone for the makers of Cialis, Eli Lilly, considering that Pfizer created the market for erectile dysfunction drugs when they first produced Viagra back in the late 1990s.
The worldwide sales of Cialis totalled $1.7 billion in 2010, representing an increase of 9 percent on the previous year. This included sales outside the USA of over $1 billion. The differences between Viagra and Cialis may be the reason why Cialis has eventually caught up with and now overtaken Viagra’s market share.
With Viagra the user takes it when they need it and the effect wears off after 4 hours. However, with Cialis there are a few more options. The stronger dosages of 10mg and 20mg have an effect which lasts for 36 hours. In France it is know as “le weekender” since its user can take one tablet which lasts the whole weekend. Alternatively, the lower dosages of 2.5mg and 5mg are meant for daily use giving users a better chance of reducing the potential side effects that may occur with regular Cialis 10mg or 20mg tablets.
It is possible that Cialis holds a psychological advantage over Viagra since it is a pill that is either taken once and lasts for a longer period of time (le weekender) or is taken on a daily basis and thus becomes seen as something akin to brushing your teeth in the morning. Either way the theory is that it does not remind the user of their failings whenever they have sex.
Another more tangible theory is that Viagra’s sales are increasingly being eroded by competition from cheap generic copies – a trend that is likely to be exacerbated when their patent on Viagra expires in March 2012. Some analysts believe this may also erode sales of Cialis with Morgan Stanley analyst David Risinger predicting Cialis sales in 2015 of just $1.4 billion.
However, City analyst John Boris predicts Cialis sales in 2015 of $2.2 billion. This scenario is based on the fact that Cialis could maintain a higher price than Viagra because the generics will not have the extended time effect of Cialis. This is because the patent on Cialis will not expire until 2017.
Furthermore, Eli Lilly is coming up with more innovative ideas to keep Cialis sales rising. In Europe they are pushing Cialis as a medication for hypertension, whilst in the U.S. they are currently seeking approval for it to be used as a treatment for middle-aged men with enlarged prostates.
The worldwide sales of Cialis totalled $1.7 billion in 2010, representing an increase of 9 percent on the previous year. This included sales outside the USA of over $1 billion. The differences between Viagra and Cialis may be the reason why Cialis has eventually caught up with and now overtaken Viagra’s market share.
With Viagra the user takes it when they need it and the effect wears off after 4 hours. However, with Cialis there are a few more options. The stronger dosages of 10mg and 20mg have an effect which lasts for 36 hours. In France it is know as “le weekender” since its user can take one tablet which lasts the whole weekend. Alternatively, the lower dosages of 2.5mg and 5mg are meant for daily use giving users a better chance of reducing the potential side effects that may occur with regular Cialis 10mg or 20mg tablets.
It is possible that Cialis holds a psychological advantage over Viagra since it is a pill that is either taken once and lasts for a longer period of time (le weekender) or is taken on a daily basis and thus becomes seen as something akin to brushing your teeth in the morning. Either way the theory is that it does not remind the user of their failings whenever they have sex.
Another more tangible theory is that Viagra’s sales are increasingly being eroded by competition from cheap generic copies – a trend that is likely to be exacerbated when their patent on Viagra expires in March 2012. Some analysts believe this may also erode sales of Cialis with Morgan Stanley analyst David Risinger predicting Cialis sales in 2015 of just $1.4 billion.
However, City analyst John Boris predicts Cialis sales in 2015 of $2.2 billion. This scenario is based on the fact that Cialis could maintain a higher price than Viagra because the generics will not have the extended time effect of Cialis. This is because the patent on Cialis will not expire until 2017.
Furthermore, Eli Lilly is coming up with more innovative ideas to keep Cialis sales rising. In Europe they are pushing Cialis as a medication for hypertension, whilst in the U.S. they are currently seeking approval for it to be used as a treatment for middle-aged men with enlarged prostates.
No comments:
Post a Comment